)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Syngene International
Syngene International (SYNGENE) investor relations material
Syngene International Q2 26/27 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 26/27 earnings summary28 Oct, 2026
Executive summary
FY27 positioned as a transition year focused on commercial execution, CDMO-led growth, differentiated discovery services and operating efficiency.
Q2 operating revenue was Rs 8,327 million, up 13% QoQ and down 9% YoY; reported PAT was Rs 322 million, below the prior-year quarter.
Sequential improvement was described as early progress; sustained growth, stronger profitability and better returns on capital remain key tests of recovery.
Financial highlights
Q2 operating EBITDA was Rs 147 crore, down 26% YoY; margin was 18%, up 6 percentage points QoQ.
A Rs 61 crore FX hedge loss weighed on Q2 EBITDA; excluding it, operating EBITDA margin was in the mid-20s.
Q2 PAT before exceptional items was Rs 38 crore; a Rs 6 crore after-tax termination-benefit charge brought reported PAT to Rs 32 crore, versus a Rs 9 crore loss in Q1.
H1 FY27 revenue was Rs 15,687 million, down from Rs 17,851 million; PAT was Rs 232 million versus Rs 1,538 million.
Consolidated Q2 net FX fluctuation loss was Rs 614 million versus Rs 118 million a year earlier; H1 loss was Rs 1,115 million versus Rs 166 million.
Outlook and guidance
FY27 EBITDA margin guidance was maintained at mid-20s excluding FX hedge losses; similar hedge losses are expected in H2 under existing forward contracts.
Manpower-cost optimization is complete, with benefits from other cost actions expected to build over coming quarters.
Bayview process development is planned in India during FY27, followed by drug-substance manufacturing in Baltimore in FY28, subject to regulatory approval for commercial supply.
H2 priorities include converting pipeline opportunities, quality and timely delivery, capacity utilization and cost discipline; one quarter does not establish sustained recovery.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Syngene International
- Q1 FY27 revenue fell 16% as margins dropped on client attrition and forex losses.SYNGENE
Q1 26/27 - FY26 revenue up 3% with Q4 rebound, but margins and profit fell; growth seen post-FY27.SYNGENEQ4 25/26
- Q3 profit dropped on labor code costs, but revenue growth and strategic investments continued.SYNGENEQ3 25/26
- APAC and India accelerate clinical CRO growth with innovation, cost, and regulatory strengths.SYNGENEStatus Update
- Q2 FY26 revenue up 2% YoY, but profit and margins fell amid FX losses and strategic investments.SYNGENEQ2 25/26
- Q2 FY25 saw flat YoY results, 13% sequential growth, and recovery in discovery and biologics.SYNGENEQ2 24/25
- Revenue and profit fell in Q1 FY25, but H2 outlook and guidance remain strong.SYNGENEQ1 24/25
- Strong revenue growth, global expansion, and early-teens outlook for FY 2026 amid margin moderation.SYNGENEQ4 24/25
- Q3 FY25 revenue grew 11% YoY with margin gains, led by biologics and contract expansions.SYNGENEQ3 24/25
Next Syngene International earnings date
Q3 26/2722 Jan, 2027
Syngene International
Next Syngene International earnings date
Q3 26/2722 Jan, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Syngene International Ltd engages in the provision of contract research and manufacturing services to the pharmaceutical, nutrition, and plant biology industries. It offers a comprehensive range of services from discovery support to manufacture of life-enabling therapies.
The company is involved in three principal activities: providing drug discovery research services; drug development services; and manufacture of active pharmaceutical ingredients & Intermediates, Recombinant proteins, Bioagrochemicals, Biosimilars & Biogenerics and also offering third party research & manufacturing services, including custom synthesis projects. The company was incorporated in 1993 and is headquartered in Bengaluru, India.